Therapeutic effect of low molecular weight heparin combined with Docetaxel for second-line treatment of advanced non-small cell lung cancer with driver gene-negative
MAO Yantao1 JIANG Maozhu2
1.Department of Oncology,Yantai Shan Hospital,Shandong Province,Yantai 264000,China;
2.Department of Radiotherapy,Yantai Shan Hospital,Shandong Province,Yantai 264000,China
Objective To investigate the clinical observation of low molecular weight heparin(LMWH)combined with Docetaxel in second-line treatment of advanced non-small cell lung cancer(NSCLC)with negative driver genes.Methods A total of 100 patients with advanced NSCLC who met the criteria and were admitted to Yantai Shan Hospital from October 2017 to September 2020 were selected as study objects,and they were divided into study group and control group according to the random number table method,with 50 cases in each group.The study group was treated with Docetaxel chemotherapy combined with LMWH.The control group was treated with Docetaxel monotherapy until disease progression or adverse reactions became intolerable.The therapeutic effect,changes of coagulation function and adverse reactions were compared between the two groups.Results There was no significant difference in the objective remission rate between the two groups after 2 cycles of treatment (P＞0.05).After treatment,the disease control rate of the study group was higher than that of the control group,and the difference was statistically significant (P＜0.05).After treatment,the D-dimer and fibrinogen（FIB）in the study group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The incidence of deep vein thrombosis in the study group was lower than that in the control group,and the difference was statistically significant (P＜0.05).There were no significant differences in the adverse reactions between the two groups (P＞0.05).Conclusion LMWH combined with Docetaxel for second-line treatment of driver gene-negative advanced NSCLC good short-term efficacy,can improve the short-term disease control rate,improve coagulation function,reduce the occurrence of venous thrombosis.
Nagaraju C，Vaidya G，Jain AS，et al.Overall Survival Prediction of Docetaxel-based Second-line Treatment for Advanced Non-small Cell Lung Cancer：A Systematic Review and Meta-analysis[J].Oman Med J，2022，37（5）：e419.
[3]
Li Y，Liang X，Li H，et al.Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection：A systematic review and network meta-analysis[J].Chin Med J，2023，136（18）：2156-2165.
[4]
Ripsman D，Fergusson DA，Montroy J，et al.A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models[J].Thromb Res，2020，11（195）：103-113.
Kagawa Y，Watanabe J，Uemura M，et al.Short-term outcomes of a prospective multicenter phase Ⅱtrial of total neoadjuvant therapy for locally advanced rectal cancer in Japan（ENSEMBLE-1）[J].Ann Gastroenterol Surg，2023，7（6）：968-976.
[7]
Singla R，Jajodia A，Agrawal RK，et al.Comparison of RECIST and iRECIST criteria in patients with advanced lung cancer treated with nivolumab[J].J Cancer Res Ther，2023，19（5）：1212-1218.
[8]
Kagawa Y，Watanabe J，Uemura M，et al.Short-term outcomes of a prospective multicenter phase Ⅱtrial of total neoadjuvant therapy for locally advanced rectal cancer in Japan（ENSEMBLE-1）[J].Ann Gastroenterol Surg，2023，7（6）：968-976.
[9]
Javadinia SA，Gholami A，Joudi Mashhad M，et al.Anti-tumoral effects of low molecular weight heparins：A focus on the treatmentofesophagealcancer[J].JCellPhysiol，2018，233（10）：6523-6529.
[10]
Abu Arab W，Kotb R，Sirois M，et al.Concentration-and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitro[J].Can J Physiol Pharmacol，2011，89（10）：705-711.
[11]
Ma SN，Mao ZX，Wu Y，et al.The anti-cancer properties of heparin and its derivatives：a review and prospect[J].Cell Adh Migr，2020，14（1）：118-128.
[12]
Quan Y，He J，Zou Q，et al.Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer[J].J Immunother Cancer，2023，11（8）：e007080.
Ponert JM，Gockel LM，Henze S，et al.Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells[J].Molecules，2018，23（10）：2690.
[15]
Qian Y，Zhang J，Xu R，et al.Nanoparticles based on polymers modified with pH-sensitive molecular switch and low molecular weight heparin carrying Celastrol and ferrocene for breast cancer treatment[J].Int J Biol Macromol，2021，31（183）：2215-2226.
[16]
Lu Z，Liu H，Ma L，et al.Micellar nanoparticles inhibit breast cancer and pulmonary metastasis by modulating the recruitment and depletion of myeloid-derived suppressor cells[J].Nanoscale，2022，14（46）：17315-17330.
Kenmotsu H，Notsu A，Mori K，et al.Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study[J].Cancer Med，2021，10（3）：895-904.
[19]
Agnelli G，Gussoni G，Bianchini C，et al.Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy：a randomised，placebo-controlled，doubleblind study[J].Lancet Oncol，2009，10（10）：943-949.
[20]
Klerk CP，Smorenburg SM，Otten HM，et al.The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy[J].J Clin Oncol，2005，23（10）：2130-2135.
[21]
Macbeth F，Noble S，Evans J，et al.Randomized Phase ⅢTrial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer：FRAGMATIC Trial[J].J Clin Oncol，2016，34（5）：488-494.
京公网安备 11010502046607号